Pasteur Merieux Report issue

Contributed to NME For profit Phase 1 Phase 4
Founded: Lyon France (1897)
Status: Acquired by Rhone Poulenc (1968) → now Sanofi-Aventis (2004)

Organization Overview

First Clinical Trial
2006
NCT00200785
First Marketed Drug
1953
thyrotropin (Thyropar)
First NDA Approval
1953
thyrotropin (Thyropar)
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

BioFire Diagnostics, LLC | Biofortis Mérieux NutriSciences | Mérieux NutriSciences Biofortis | Silliker, Inc. | Silliker, Inc./Plant Bioactives Research Institute

Active Ingredients

Marketed Drugs (1)

thyrotropin (Thyropar) (1953 NDA)

Drugs in Phase 4 Trials (1)

Key: Pasteur Merieux (0) Acquired (1)

procaine benzylpenicillin (novocaine) (1 trial)

Drugs in Phase 1 Trials (1)

garlic (2 trials)

Drugs in Other Trials (12)

Key: Pasteur Merieux (11) Acquired (1)

bifidobacterium lactis (1 trial)

c6 ketone di-ester (2 trials)

erythritol (1 trial)

fiber (1 trial)

gingerol (1 trial)

ketone monoester (1 trial)

maltodextrin (1 trial)

sc-fos (1 trial)

thiethylperazine (torecan) (1 trial)

thiocarb (1 trial)

totum-63 (1 trial)

turmeric (1 trial)

Indications

Overview

  • Highest Phase: Phase 1
  • # of Trials: 14
  • # of Trial APIs: 14